151 related articles for article (PubMed ID: 31489288)
1. Adjuvant chemotherapy in stage II-III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX.
Ramaswamy A; Kothari R; Desouza A; Gupta T; Bairwa S; Kapoor A; Kumar A; Ventrapati P; Ramadwar M; Mandavkar S; Chavan N; Saklani A; Ostwal V
South Asian J Cancer; 2019; 8(3):160-165. PubMed ID: 31489288
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
3. Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients.
van Erning FN; Razenberg LG; Lemmens VE; Creemers GJ; Pruijt JF; Maas HA; Janssen-Heijnen ML
Eur J Cancer; 2016 Jul; 61():1-10. PubMed ID: 27128782
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study.
Osawa H; Handa N; Minakata K
Oncol Res; 2014; 22(5-6):325-31. PubMed ID: 26629945
[TBL] [Abstract][Full Text] [Related]
5. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
[TBL] [Abstract][Full Text] [Related]
6. Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.
Loree JM; Sha A; Soleimani M; Kennecke HF; Ho MY; Cheung WY; Mulder KE; Abadi S; Spratlin JL; Gill S
Clin Colorectal Cancer; 2018 Jun; 17(2):156-163. PubMed ID: 29486916
[TBL] [Abstract][Full Text] [Related]
7. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study).
Nakayama G; Takano N; Taniguchi H; Ishigure K; Yokoyama H; Teramoto H; Hashimoto R; Sakai M; Ishiyama A; Kinoshita T; Hayashi N; Nakamura M; Hattori N; Sato Y; Umeda S; Uehara K; Aiba T; Sonohara F; Hayashi M; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Murotani K; Ando M; Ando Y; Muro K; Kodera Y
Eur J Cancer; 2021 Feb; 144():61-71. PubMed ID: 33340853
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
[TBL] [Abstract][Full Text] [Related]
9. Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
Yoshino T; Oki E; Misumi T; Kotaka M; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Nakamura F; Bando H; Taniguchi H; Sakamoto Y; Shiozawa M; Nishi M; Horiuchi T; Yamagishi H; Sakamoto J; Mizushima T; Ohtsu A; Mori M
J Clin Oncol; 2022 Oct; 40(29):3419-3429. PubMed ID: 35512259
[TBL] [Abstract][Full Text] [Related]
10. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.
Loree JM; Mulder KE; Ghosh S; Spratlin JL
Clin Colorectal Cancer; 2014 Sep; 13(3):172-7. PubMed ID: 24630275
[TBL] [Abstract][Full Text] [Related]
11. Clinical Practice in the Use of Adjuvant Chemotherapy for Patients with Colon Cancer in South Korea: a Multi-Center, Prospective, Observational Study.
Kim JH; Baek MJ; Ahn BK; Kim DD; Kim IY; Kim JS; Bae BN; Seo BG; Jung SH; Hong KH; Kim H; Park DG; Lee JH
J Cancer; 2016; 7(2):136-43. PubMed ID: 26819636
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa.
Tan SX; Pumpalova Y; Rogers AM; Bhatt K; Herbst CL; Ruff P; Neugut AI; Hur C
Cancer Med; 2023 Jul; 12(14):15515-15529. PubMed ID: 37318753
[TBL] [Abstract][Full Text] [Related]
13. Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study.
Sha A; Abadi S; Gill S
J Oncol Pharm Pract; 2018 Oct; 24(7):501-506. PubMed ID: 28714378
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
Yoshino T; Yamanaka T; Oki E; Kotaka M; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Takeuchi S; Bando H; Taniguchi H; Gamoh M; Shiozawa M; Mizushima T; Saji S; Maehara Y; Ohtsu A; Mori M
JAMA Oncol; 2019 Nov; 5(11):1574-1581. PubMed ID: 31513248
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically.
Bardakci M; Demirtas Esmer D; Hafizoglu E; Yaslikaya S; Genc TB; Ozcelik M; Erdat EC; Hendem E; Buyukbayram ME; Alaca Topcu Z; Kalkan Z; Yildirim N; Celebi A; Ergun Y; Paydas S; Tatli AM; Karakas H; Koseci T; Sendur MAN
Oncology; 2023; 101(11):723-729. PubMed ID: 37379817
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.
Yamazaki K; Yamanaka T; Shiozawa M; Manaka D; Kotaka M; Gamoh M; Shiomi A; Makiyama A; Munemoto Y; Rikiyama T; Fukunaga M; Ueki T; Shitara K; Shinkai H; Tanida N; Oki E; Sunami E; Ohtsu A; Maehara Y; Yoshino T
Ann Oncol; 2021 Jan; 32(1):77-84. PubMed ID: 33121997
[TBL] [Abstract][Full Text] [Related]
18. Changes in Prescribing Patterns in Stage III Colon Cancer.
Ou FS; Walden DJ; Larson JJ; Kang S; Griswold CR; Ueberroth BE; Patel B; Draper A; Raman P; Alese OB; Sonbol MB; Bekaii-Saab TS; Wu CS; Ahn DH
J Natl Compr Canc Netw; 2023 Aug; 21(8):841-850.e4. PubMed ID: 37549913
[TBL] [Abstract][Full Text] [Related]
19. The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis.
Breadner D; Loree JM; Cheung WY; Gipson M; Lakkunarajah S; Mulder KE; Spartlin JL; Kong S; Ding PQ; Gill S; Welch SA
BMC Cancer; 2022 Nov; 22(1):1119. PubMed ID: 36319973
[TBL] [Abstract][Full Text] [Related]
20. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
